Atlas Trials

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Clinical trial NCT01215578 · TERMINATED

Trial details

NCT number
NCT01215578
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced DiseaseSunitinib
Start date
2008-10-01
Primary completion
2013-12-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.